Terns Pharmaceuticals Inc. (NASDAQ: TERN) Climbs 29% Following Trial Results with TERN-601 Once-Daily Oral GLP-1R ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Trader Talk

Terns Pharmaceuticals (TERN) PT Raised to $30 at Jefferies Following +16% Gain TodaySeptember 9, 2024 4:00 PM Terns Pharmaceuticals (TERN) Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of ObesitySeptember 9, 2024 7:05 AM Terns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of ObesitySeptember 9, 2024 7:05 AM